A Neurologist's Perspective on Understanding Myasthenia Gravis Clinical Perspectives of Etiologic Factors, Diagnosis, and Preoperative Treatment

被引:5
作者
Mukharesh, Loulwah [1 ]
Kaminski, Henry J. [1 ]
机构
[1] George Washington Univ, Dept Neurol, 2150 Penn Ave,NW 9th Floor, Washington, DC 20037 USA
关键词
Myasthenia gravis; Autoimmune disease; Neuromuscular junction; Thymectomy; OCULAR MYASTHENIA; DOUBLE-BLIND; MUSK; RITUXIMAB; CELLS; IMMUNOGLOBULIN; AZATHIOPRINE; THYMECTOMY; EFFICACY; UPDATE;
D O I
10.1016/j.thorsurg.2018.12.002
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Myasthenia gravis (MG) is a disease of neuromuscular transmission caused by antibodies directed toward proteins concentrated at the neuromuscular junction. Mild to life-threatening weakness varies in severity over time and with level of activity. Therefore, clinical diagnosis is often challenging. MG may be categorized by autoantibody type, thymic pathologic condition, and age of onset. Treatments are tailored for each group. A key management concern is severe exacerbation of weakness resulting from infections or exposure to certain medications, including antibiotics, which may be severe enough to produce respiratory decompensation. The article reviews key diagnostic issues and treatment options.
引用
收藏
页码:133 / +
页数:10
相关论文
共 68 条
[51]   International consensus guidance for management of myasthenia gravis: Executive summary [J].
Sanders, Donald B. ;
Wolfe, Gil I. ;
Benatar, Michael ;
Evoli, Amelia ;
Gilhus, Nils E. ;
Illa, Isabel ;
Kuntz, Nancy ;
Massey, Janice M. ;
Melms, Arthur ;
Murai, Hiroyuki ;
Nicolle, Michael ;
Palace, Jacqueline ;
Richman, David P. ;
Verschuuren, Jan ;
Narayanaswami, Pushpa .
NEUROLOGY, 2016, 87 (04) :419-425
[52]  
Shapiro BE., 2013, ELECTROMYOGRAPHY NEU, P52
[53]  
Simpson J.A., 1960, SCOTT MED J, V5, P419, DOI [10.1177/003693306000501001, DOI 10.1177/003693306000501001]
[54]   Update on Ocular Myasthenia Gravis [J].
Smith, Stacy V. ;
Lee, Andrew G. .
NEUROLOGIC CLINICS, 2017, 35 (01) :115-+
[55]  
Sonett JR, 2018, MYASTHENIA GRAVIS RE, V10, P199
[56]  
Sussman Jon, 2015, Pract Neurol, V15, P199, DOI 10.1136/practneurol-2015-001126
[57]   Long-term efficacy and side effects of low-dose tacrolimus for the treatment of Myasthenia Gravis [J].
Tao, Xiaoyong ;
Wang, Wei ;
Jing, Feng ;
Wang, Zhongkui ;
Chen, Yuping ;
Wei, Dongning ;
Huang, Xusheng .
NEUROLOGICAL SCIENCES, 2017, 38 (02) :325-330
[58]   Opportunistic infections in myasthenia gravis treated with mycophenolate mofetil [J].
Termsarasab, Pichet ;
Katirji, Bashar .
JOURNAL OF NEUROIMMUNOLOGY, 2012, 249 (1-2) :83-85
[59]   Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil [J].
Vernino, S ;
Salomao, DR ;
Habermann, TM ;
O'Neill, BP .
NEUROLOGY, 2005, 65 (04) :639-641
[60]  
Walker M B, 1935, Proc R Soc Med, V28, P759